Pharmacological intervention to inhibit the myostatin pathway is therefore considered an attractive therapeutic approach for various types of muscle disorders, such as muscular dystrophy and atrophy, for which no effective treatment is currently available. This evidence concerns the gene MSTN and muscular disease.